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A B S T R A C T
Importance: Schizophrenia and major depressive disorder (MDD) are associated with increased risks of im-
munologic disease and metabolic syndrome. It is unclear to what extent growth, immune or glucose dysregu-
lations are similarly present in these disorders without the influence of treatment or chronicity.
Objective: To conduct a meta-analysis investigating whether there are altered peripheral growth, immune or
glucose metabolism compounds in drug-naïve first-episode patients with schizophrenia or MDD compared with
controls.
Data sources and study selection: Case-control studies reporting compound measures in drug-naïve first-episode
patients with schizophrenia or MDD compared with controls in the Embase, PubMed and PsycINFO databases.
Data extraction and synthesis: Two independent authors extracted data for a random-effects meta-analysis.
Main outcomes and measures: Peripheral growth, immune or glucose metabolism compounds in schizophrenia or
MDD compared with controls. Standardized mean differences were quantified with Hedges’ g (g).
Results: 74 studies were retrieved comprising 3453 drug-naïve first-episode schizophrenia patients and 4152
controls, and 29 studies were retrieved comprising 1095 drug-naïve first-episode MDD patients and 1399 con-
trols. Growth factors: brain-derived neurotrophic factor (BDNF) (g = -0.77, P < .001) and nerve growth factor
(NGF) (g = -2.51, P = .03) were decreased in schizophrenia. For MDD, we observed a trend toward decreased
BDNF (g = −0.47, P = .19) and NGF (g = −0.33, P = .08) levels, and elevated vascular endothelial growth
factor levels (g = 0.40, P = .03). Immune factors: interleukin (IL)-6 (g = 0.95, P < .001), IL-8 (g = 0.59,
P = .001) and tumor necrosis factor alpha (TNFα) (g = 0.48, P = .002) were elevated in schizophrenia. For C-
reactive protein (CRP) (g = 0.57, P= .09), IL-4 (g = 0.44, P= .10) and interferon gamma (g = 0.33, P= .11)
we observed a trend toward elevated levels in schizophrenia. In MDD, IL-6 (g = 0.62, P = .007), TNFα
(g = 1.21, P < .001), CRP (g = 0.53, P< .001), IL-1β (g = 1.52, P = .009) and IL-2 (g = 4.41, P= .04) were
elevated, whereas IL-8 (g = −0.84, P = .01) was decreased. The fasting glucose metabolism factors glucose
(g = 0.24, P = .003) and insulin (g = 0.38, P = .003) were elevated in schizophrenia.
Conclusions and relevance: Both schizophrenia and MDD show alterations in growth and immune factors from
disease onset. An altered glucose metabolism seems to be present from onset in schizophrenia. These findings
support efforts for further research into transdiagnostic preventive strategies and augmentation therapy for those
with immune or metabolic dysfunctions.
1. Introduction
Traditionally, schizophrenia and major depressive disorder (MDD)
are seen as separate disorders based on their distinct clinical pre-
sentation. In clinical practice, however, overlapping symptoms are
noticeable such as psychotic symptoms, apathy and cognitive
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dysfunction (Hill et al., 2009). Moreover, genetic and environmental
risk factors point towards shared vulnerability between both disorders.
A large genome-wide study showed that single-nucleotide polymorph-
isms are shared between major psychiatric disorders including schizo-
phrenia and MDD (Lee et al., 2013). Environmental risk factors for
development of psychopathology such as the experience of stress, ur-
banicity or low socioeconomic status increase risk for all psychiatric
diagnoses (Buckholtz and Meyer-Lindenberg, 2012).
Impairment of neuroplasticity and vascularization in the brain are
thought to underlie schizophrenia and MDD (Rao et al., 2017;
Birkenhager et al., 2012; Xie et al., 2017; Brugger and Howes, 2017;
Chen et al., 2017). Neurotrophic factors, including brain derived neu-
rotrophic factor (BDNF), contribute to neuroplasticity, and are there-
fore key components for cognition, which is a well-known key dys-
function of both schizophrenia and MDD (Rao et al., 2017; Benraiss
et al., 2001; Pencea et al., 2001). Reduced BDNF levels in peripheral
blood have often been demonstrated in schizophrenia and MDD
(Fernandes et al., 2015; Molendijk et al., 2014). Increasing evidence
shows that neuroinflammation plays an important role in the patho-
physiology of schizophrenia and MDD, in both disorders components of
the immune system in the brain (i.e. microglia) are in an altered state of
activity (Fineberg and Ellman, 2013; Brites and Fernandes, 2015). As a
result, microglia and other glia may reduce their neurotrophic function
and produce less growth factors, such as BDNF, leading to decreased
neuron proliferation, resulting in reduced connectivity and this may
finally result in neurodegeneration (Brites and Fernandes, 2015; Chew
et al., 2013). Neuroinflammation may enhance the production of per-
ipheral neurotoxic inflammatory factors (Monji et al., 2009; Drexhage
et al., 2011).
There is accumulating evidence that dysregulations in components
of the immune system are linked to schizophrenia and MDD. Findings of
a large Danish cohort study suggest the existence of shared immune
factors for schizophrenia and endocrine autoimmune diseases (in-
cluding type 1 diabetes) as they have a relatively high familial co-oc-
currence (Eaton et al., 2010). Genetic associations show that patients
with schizophrenia or MDD on average may have an immune system
subtly more prone to being activated, as expressed for example in major
histocompatibility complex molecules in schizophrenia and associa-
tions between polymorphisms in immune genes and MDD (Debnath
et al., 2013; Mokhtari and Lachman, 2016; Barnes et al., 2017). There is
meta-analytic evidence that peripheral cytokines are altered in first-
episode psychosis (Pillinger et al., 2018) and in depression (Kohler
et al., 2017). It has been suggested that both anti- and pro-in-
flammatory factors play a role in healthy brain functioning, and that an
imbalance in these factors may lead to detrimental consequences for the
brain (Golia et al., 2019). Brain function can be altered by im-
munological or hormonal changes originating in the periphery, i.e. the
brain is integrated in biological functions of the body which is reflected
by changes in the molecular composition of the blood (Chan et al.,
2014).
Impaired cerebral glucose utilization in brain areas could also play
an important role in the pathogenesis of psychiatric disorders, ex-
emplified by metabolic disconnection of the dorsolateral prefrontal
cortex and mediodorsal thalamus with the limbic system in schizo-
phrenia (Steiner et al., 2014; Buchsbaum et al., 2007; Mitelman et al.,
2005). There is meta-analytic evidence for peripheral glucose metabo-
lism alterations in (antipsychotic-naïve) first-episode patients with
schizophrenia compared with controls (Pillinger et al., 2017;
Greenhalgh et al., 2017; Perry et al., 2016; Kucukgoncu et al., 2019). A
prospective cohort study of a general population sample found an in-
creased incidence of metabolic syndrome and increased fasting glucose
levels in the atypical MDD subtype, which could not be attributed to
lifestyle factors alone (Lasserre et al., 2017). Taken together, these al-
terations in growth, immune or glucose metabolism compounds may
point to shared neurobiological processes between schizophrenia and
MDD.
Therefore, in recent years there has been an increasing interest in
the transdiagnostic aspects of schizophrenia and MDD (Wigman et al.,
2015; Van Os et al., 2009). Accumulating evidence presents similarity
in altered growth, immune and glucose metabolism factors in schizo-
phrenia and MDD. However, most studies report measurements of
peripheral blood compounds of patients who use psychotropic medi-
cation or are chronically ill. Therefore, it is unknown to what extent
treatment or other factors associated with chronicity influence these
alterations in both disorders. A better understanding of the underlying
pathophysiology of both psychiatric disorders is mandatory in order to
plan for shared preventive strategies and treatment regarding immune
and metabolic dysfunctions prevalent in these disorders.
In this meta-analysis we aimed to answer the following question:
which peripheral growth, immune or glucose metabolism compounds
are altered in drug-naïve first-episode patients with either schizo-
phrenia or MDD compared with healthy controls? Moreover, we aimed
to answer the question whether altered compounds in schizophrenia or
MDD are changed in a similar or dissimilar direction and magnitude.
2. Methods
2.1. Study selection
The literature was systematically reviewed according to PRISMA
(Preferred Reporting Items for Systematic Reviews and Meta-analyses)
and MOOSE (Meta-analysis of Observational Studies in Epidemiology)
guidelines (Supplementary Tables 1 and 2) (Moher et al., 2009; Stroup
et al., 2000). Two independent investigators (N.Ç. and N.v.B.) searched
the PubMed, Embase and PsycINFO databases from inception to Jan-
uary 19th, 2019, for meta-analyses, systematic reviews and case-control
studies that reported measurements of peripheral blood compounds
which are involved in growth, immune and metabolic processes in
drug-naïve first-episode patients with either schizophrenia or MDD
compared with healthy controls. Details of the search strategy are
provided in Supplementary Table 3. We first screened for meta-analyses
and systematic reviews that systematically searched for peripheral
blood compounds in schizophrenia and MDD, which did not necessarily
restrict their inclusions to drug-naïve or first-episode patients. Next, we
extracted drug-naïve first-episode case-control studies from meta-ana-
lyses and systematic reviews with high quality, as assessed with the
Assessing the Methodological Quality of Systematic Reviews quality
assessment. For our final inclusion of studies, we screened for drug-
naïve first-episode case-control studies starting from the last search date
of inclusion in the retrieved meta-analyses or systematic reviews. If
high-quality meta-analyses or systematic reviews were not available for
a respective compound, we searched for drug-naïve first-episode case-
control studies that reported measurements of these compounds from
inception. No language restrictions were applied. Authors were con-
tacted if additional data was needed for analysis (e.g., if drug-naïve or
first-episode patients were only a subset of the total study population).
We contacted authors for full report of relevant unpublished studies.
We completed the search by hand-searching additional relevant
meta-analyses, systematic reviews and case-control studies.
Disagreements were resolved by discussion with another author
(L.d.H.).
2.2. Inclusion criteria
Inclusion criteria were (1) observational studies including a control
group; (2) a Diagnostic and Statistical Manual of Mental Disorders
(DSM) or International Statistical Classification of Diseases (ICD) di-
agnosis of schizophrenia, schizophreniform disorder or MDD; (3) a
healthy control group; (4) assessment of peripheral compounds in
serum or plasma which are involved in growth, immune or metabolic
processes; (5) peripheral compounds that are involved in the glucose
homeostasis under fasting conditions; (6) antipsychotic-naïve patients
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with schizophrenia and antidepressant-naïve patients with MDD; (8)
first-episode of disease.
2.3. Data extraction and processing
Two authors (N.Ç. and N.v.B.) independently extracted means and
standard deviation of measures of growth, immune and glucose meta-
bolism compounds from the retrieved case-control studies. If there were
multiple publications from the same cohort, we extracted data from the
largest or most recent data set.
To identify quality of the studies we used the Newcastle-Ottawa
quality assessment scale (NOS) (Wells et al., 2009). For sensitivity
analyses we re-ran our analyses including high-quality studies only: as a
cut-off value for high-quality studies we chose that all case-control
studies should meet at least two thirds of the NOS criteria, implying a
cut-off score of 6.
2.4. Statistical analysis
We included a compound for analysis if at least two studies reported
measurements on the respective compound. We calculated standardized
mean differences, represented as Hedges’ g, using random-effects meta-
analyses. A random-effects model was used in all compounds as we
expected high heterogeneity of data across studies. Since the study
mean differences are first standardized before weighting is applied,
effect sizes could be directly compared across different measurement
scales. We assessed heterogeneity across studies using the Cochran Q
statistic (Bowden et al., 2011). Inconsistency across studies was as-
sessed with the I2 statistic, with assigning adjectives of low, moderate
and high heterogeneity to I2 values of 0–<25%, 25%–75% and >75%
(Higgins et al., 2003). Since, we observed heterogeneity in the included
studies, we used the method of DerSimonian and Laird for calculating
the random-effects pooled effect size and 95% confidence interval to
provide a lower type I error. We assessed potential publication bias
using the Egger test of the intercept (Egger et al., 1997) if 10 or more
studies were analysed for the same compound with funnel plots
(Supplementary Figs. 1–8) (as recommended by the Cochrane Colla-
boration). Additionally, we compared the effect sizes statistically of
each compound between schizophrenia and MDD using a Wald-type
test (Pillinger et al., 2019). We entered each pair of effect size into a
fixed effects model, given that the residual heterogeneity has already
been accounted for in the initial random effects meta-analyses. Next, we
calculated subgroup summary effect size magnitudes by running a
combined analysis of all studies assigned to a subgroup, i.e. growth,
immune, and glucose. Subsequently, we statistically compared the
subgroup summary effect sizes of growth, immune, and glucose in
schizophrenia versus MDD. Finally, in a sensitivity analysis, we re-
stricted our analyses to high-quality studies only to reassess the direc-
tion of change and magnitude of the compounds in schizophrenia and
MDD. We considered a 2-tailed P value <0.05 as significant for all
analyses. All analyses were performed using the meta- and metafor-
packages (Schwarzer, 2007; Viechtbauer, 2010) in R software 3.4.0 (R
Development Core Team, 2008).
2.5. Terminology
To keep in line with most authors we chose to use the term first-
episode schizophrenia, however not all patients with a first episode of
psychosis included fulfil DSM or ICD criteria of schizophrenia.
Therefore, it would be appropriate to mention that these patients had
experienced a first episode of schizophrenia or a related disorder.
3. Results
3.1. Retrieved studies
A total of 74 case-control studies were retrieved comprising of 3453
drug-naïve and first-episode schizophrenia patients and 4152 controls,
and a total of 29 studies were retrieved comprising of 1095 drug-naïve
and first-episode MDD patients and 1399 controls. Of the following 17
compounds at least two studies were available for meta-analysis for
both disorders: growth factors BDNF, nerve growth factor (NGF), and
vascular endothelial growth factor (VEGF); immune factors C-reactive
protein (CRP), interferon gamma (IFNγ), interleukin (IL)-1β, IL-2, IL-4,
IL-6, IL-8, IL-10, IL-12, monocyte Chemoattractant Protein-1 (MCP-1),
and transforming growth factor beta (TGF-β), tumor necrosis factor
alpha (TNFα); glucose factors fasting glucose and insulin concentration.
The selection process is presented in Supplementary Fig. 9. Study
characteristics such as setting, number of patients and controls, gender,
age and type of control matching are provided in Supplementary
Table 4. Additional study characteristics such as catchment area,
sample source (serum or plasma), fasting state and criteria used for
patients and controls in the included studies are provided in
Supplementary Tables 5 and 6. The risk of bias of the included studies is
provided in Supplementary Table 7.
3.2. Growth factors
Fig. 1 shows the effect sizes for growth factors in drug-naïve first-
episode patients with schizophrenia or MDD compared with controls.
Schizophrenia patients showed significantly decreased levels of
BDNF (g = −0.77; 95% CI, −0.97 to −0.56; P < .001; I2 = 78%)
(Fig. 2) and NGF (Fig. 3) (g = −2.51; 95% CI, −4.80 to −0.21;
P = .03; I2 = 98%) compared with controls. No indication of pub-
lication bias for BDNF studies was found (Egger test P= .19). For MDD
patients, we found a trend of decreased BDNF levels (g = −0.47; 95%
CI, −1.18 to 0.24; P = .19; I2 = 95%), without indication of pub-
lication bias (Egger test P = .37), and a trend toward decreased NGF
levels (g = −0.33; 95% CI, −0.69 to 0.04; P = .08; I2 = 0%) com-
pared with controls.
Fig. 1. Forest Plot Showing Effect Sizes for Growth Factors in Drug-Naïve First-Episode Schizophrenia and MDD.
Diamonds illustrate the summary effect sizes, the middle of each diamond represents the summary effect size, and the width of the diamond depicts the width of the
overall 95% CI. Abbreviations: BDNF, brain-derived neurotrophic factor; MDD, major depressive disorder; NGF, nerve growth factor; VEGF, vascular endothelial
growth factor.
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Conversely, VEGF levels were not altered in schizophrenia patients
(g = 0.25; 95% CI, −0.28 to 0.78; P = .35; I2 = 79%), whereas MDD
patients showed significantly elevated VEGF levels compared with
controls (g = 0.40; 95% CI, 0.05 to 0.75; P = .03; I2 = 0%). See
Supplementary Figs. 10–12 for effect size estimates for individual stu-
dies.
3.3. Immune factors
Fig. 4 shows the effect sizes for immune factors in drug-naïve first-
episode patients with schizophrenia or MDD compared with controls.
For CRP, we observed a trend of increased levels in schizophrenia
patients compared with controls (g = 0.57; 95% CI, −0.09 to 1.23;
P = .09; I2 = 93%). CRP levels were significantly increased in MDD
with a similar effect size compared with schizophrenia (g = 0.53; 95%
CI, 0.24 to 0.82; P< .001; I2 = 41%). For IFNγ, we observed a trend of
Fig. 2. BDNF Levels in Patients with Drug-Naïve First-Episode Schizophrenia or MDD and Controls.
Each square resembles the effect size for a single study. The horizontal line running through each square illustrates the width of the 95% CI. The size of the squares
reflects the weight attributed to each study. Diamonds illustrate the summary effect sizes and the width of the diamonds reflect the width of the overall 95% CI.
Abbreviations: BDNF, Brain-Derived Neurotrophic Factor; MDD, Major Depressive Disorder.
Fig. 3. NGF Levels in Patients with Drug-Naïve First-Episode Schizophrenia or MDD and Controls.
Each square resembles the effect size for a single study. The horizontal line running through each square illustrates the width of the 95% CI. The size of the squares
reflects the weight attributed to each study. Diamonds illustrate the summary effect sizes and the width of the diamonds reflect the width of the overall 95% CI.
Abbreviations: NGF, Nerve Growth Factor; MDD, Major Depressive Disorder.
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elevated levels in schizophrenia (g = 0.33; 95% CI, −0.08 to 0.73;
P = .11; I2 = 83%). MDD patients did not show significantly altered
IFNγ levels compared with controls (g = −0.33; 95% CI, −1.31 to
0.66; P = .51; I2 = 87%). IL-1β levels were not significantly altered in
schizophrenia (g = 0.42; 95% CI, −0.30 to 1.15; P = .25; I2 = 94%).
MDD patients showed significantly elevated IL-1β levels compared with
controls (g = 1.52; 95% CI, 0.38 to 2.66; P = .009; I2 = 96%). IL-2
levels were not altered in schizophrenia patients compared with
controls (g = 0.13; 95% CI, −0.38 to 0.63; P = .63; I2 = 87%). No
indication of publication bias was found (Egger test P = .14). MDD
patients showed significantly elevated IL-2 levels compared with con-
trols (g = 4.41; 95% CI, 0.13 to 8.69; P = .04; I2 = 98%). For IL-4, we
observed a trend of elevated levels in schizophrenia (g = 0.44; 95% CI,
−0.08 to 0.96; P = .10; I2 = 88%). IL-4 levels were not significantly
altered in MDD patients compared with controls (g = -1.71; 95% CI,
−4.73 to 1.31; P = .27; I2 = 97%). IL-6 levels were significantly
Fig. 4. Forest Plot Showing Effect Sizes for Immune Factors in Drug-Naïve First-Episode Schizophrenia and MDD.
Diamonds illustrate the summary effect sizes, the middle of each diamond represents the summary effect size, and the width of the diamond depicts the width of the
overall 95% CI. Abbreviations: CRP, C-reactive protein; IFNγ, interferon gamma; IL, interleukin; MCP-1, monocyte chemoattractant protein 1; MDD, major depressive
disorder; TGFß, transforming growth factor beta; TNFα, tumor necrosis factor alpha.
Fig. 5. IL-6 Levels in Patients with Drug-Naïve First-Episode Schizophrenia or MDD and Controls.
Each square resembles the effect size for a single study. The horizontal line running through each square illustrates the width of the 95% CI. The size of the squares
reflects the weight attributed to each study. Diamonds illustrate the summary effect sizes and the width of the diamonds reflect the width of the overall 95% CI.
Abbreviations: IL, Interleukin; MDD, Major Depressive Disorder.
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elevated in schizophrenia patients compared with controls (g = 0.95;
95% CI, 0.57 to 1.32; P < .001; I2 = 88%) (Fig. 5). Findings of the
Egger test (P= .31) suggested that publication bias was not significant.
IL-6 levels were also significantly elevated in MDD patients compared
with controls (g= 0.62; 95% CI, 0.17 to 1.06; P= .007; I2 = 85%). IL-
8 levels were significantly elevated in schizophrenia patients compared
with controls (g= 0.59; 95% CI, 0.23 to 0.95; P= .001; I2 = 54%). In
contrast to schizophrenia, IL-8 levels were significantly decreased in
MDD patients compared with controls (g = −0.84; 95% CI, −1.48 to
−0.20; P = .01; I2 = 76%). IL-10 levels were not significantly altered
in schizophrenia patients compared with controls (g = 0.13; 95% CI,
−0.21 to 0.46; P = .46; I2 = 85%). Indication of publication bias was
not present (Egger test P = .77). In MDD, IL-10 levels were also not
significantly altered (g = −0.75; 95% CI, −2.77 to 1.28; P = .47;
I2 = 98%). For IL-12, we observed no altered levels in schizophrenia
(g = 0.35; 95% CI, −0.20 to 0.91; P = .22; I2 = 0%) and MDD
(g = 1.92; 95% CI, −1.10 to 4.94; P = .22; I2 = 97%). MCP-1 levels
were not significantly altered in schizophrenia patients (g = 0.29; 95%
CI, −0.24 to 0.81; P = .29; I2 = 56%) nor in MDD patients (g = 1.89;
95% CI, −1.06 to 4.84; P = .21; I2 = 97%), compared with controls.
TGF-β levels were not significantly altered in schizophrenia patients
compared with controls (g = 4.16; 95% CI, −4.03 to 12.34; P = .32;
I2 = 99%). For MDD, we observed a trend of decreased TGF-β levels
(g = −0.91; 95% CI, −1.98 to 0.16; P = .10; I2 = 95%). TNFα levels
were significantly elevated in schizophrenia patients compared with
controls (g= 0.48; 95% CI, 0.19 to 0.78; P= .002; I2 = 75%) (Fig. 6).
Findings of the Egger test (P= .77) suggested that publication bias was
not significant. TNFα levels were also significantly elevated in MDD
patients compared with controls (g = 1.21; 95% CI, 0.57 to 1.85;
P < .001; I2 = 89%). See Supplementary Figs. 13–24 for effect size
estimates for individual studies.
3.4. Glucose metabolism factors
Fig. 7 shows the effect sizes for fasting glucose metabolism factors in
drug-naïve first-episode patients with schizophrenia or MDD compared
with controls.
Fasting glucose concentration was significantly elevated in schizo-
phrenia patients compared with controls (g = 0.24; 95% CI, 0.08 to
0.39; P = .003; I2 = 62%) (Fig. 8). Indication of publication bias was
not present (Egger test P = .20). For MDD patients, glucose levels
seemed to be higher in MDD patients, but this difference did not reach
statistical significance (g = 0.12; 95% CI, −0.07 to 0.32; P = .22;
I2 = 0%). Fasting insulin concentration was significantly elevated in
schizophrenia patients compared with controls (g= 0.38; 95% CI, 0.13
to 0.64; P = .003; I2 = 75%). No indication of publication bias was
found (Egger test P = .17). MDD patients did not show altered fasting
insulin concentration levels compared with controls (g= -0.09; 95% CI,
−0.64 to 0.47; P= .75; I2 = 76%). See Supplementary Figs. 25 and 26
for effect size estimates for individual studies.
3.5. Statistical comparison of effect sizes
We statistically compared the overall magnitude of alteration of
compounds separately in schizophrenia versus MDD using a Wald-type
test (Supplementary Table 8). For IL-8, we observed a statistical dif-
ference of the overall effect size in schizophrenia versus MDD (Wald
score: 3.82; P< .005). For all other compounds there was no significant
difference between the overall effect size of alterations in schizophrenia
versus MDD.
Next, we statistically compared the subgroup summary effect sizes
of growth, immune, and glucose in schizophrenia versus MDD. There
was no significant difference between the overall effect size of altera-
tions of growth and immune compounds in schizophrenia versus MDD
(P = .117 and P = .625, respectively). The overall effect size of al-
terations of glucose compounds in schizophrenia was significantly
higher than in MDD (Wald score: 0.27; P = .042).
3.6. Effect of study quality
In a sensitivity analysis, we restricted our analyses to high-quality
studies indicated by a cut-off score of 6 or more NOS criteria
(Supplementary Tables 7 and 9). Our results of similarly altered im-
mune factors, IL-6 and TNFα, remained comparable in both schizo-
phrenia (P < .0001 and P < .01, respectively) and MDD (P < .01 and
P< .001, respectively). Also, growth factor BDNF was still decreased in
schizophrenia (P < .0001), but for growth factor NGF we observed a
trend of decreased levels using two studies (P = .09). In MDD, BDNF
levels were not significantly altered (P = .28), and NGF portrayed a
trend of decreased levels (P = .08). Compared to the initial meta-
Fig. 6. TNFα Levels in Patients with Drug-Naïve First-Episode Schizophrenia or MDD and Controls.
Each square resembles the effect size for a single study. The horizontal line running through each square illustrates the width of the 95% CI. The size of the squares
reflects the weight attributed to each study. Diamonds illustrate the summary effect sizes and the width of the diamonds reflect the width of the overall 95% CI.
Abbreviations: MDD, Major Depressive Disorder; TNFα, Tumor necrosis factor alpha.
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analysis, both schizophrenia and MDD now showed increased VEGF
levels (P = .03 and P = .03, respectively) that were significant. The
results for immune factor CRP remained the same for schizophrenia, a
trend of increased levels (P = .09), and for MDD, increased levels
(P = .03). Immune factor IL-1β remained elevated in MDD (P < .01).
In contrast to our initial meta-analysis, we did not observe altered IL-2
levels in MDD using two studies (P = .27). In the current sensitivity
analysis, immune factor IL-8 was still increased in schizophrenia
(P = .03) and decreased in MDD (P < .01). Compared to the initial
meta-analysis, for schizophrenia, the increased levels of IL-4 (P= 0.02)
and IL-10 (P < .01) became significant. For immune factor TGF-β we
observed a trend of elevated levels in MDD (P < .10). Glucose meta-
bolism factors fasting glucose concentration and fasting insulin con-
centration remained elevated in schizophrenia (P < .01 and P = .01,
respectively).
4. Discussion
In this meta-analysis, we found that drug-naïve first-episode pa-
tients with either schizophrenia or MDD show generally similar but
some different changes in growth factors, immune factors and glucose
metabolism. Growth factors BDNF and NGF were decreased in schizo-
phrenia, and growth factor VEGF was elevated in MDD. Both schizo-
phrenia and MDD show significantly elevated levels of immune factors
IL-6 and TNF-α. For other immune factors we observed a differentiated
representation of significant alterations in schizophrenia and MDD.
Immune factor IL-8 was elevated in schizophrenia and, in contrast,
decreased in MDD. Immune factors CRP, IL-1β and IL-2 were elevated
in MDD. Glucose metabolism factors fasting glucose and fasting insulin
were elevated in schizophrenia. The overall magnitude of alteration for
subgroups growth and immune were not statistically different between
schizophrenia and MDD, except for glucose, for which the effect size
was higher for schizophrenia.
Our findings suggest that dysfunctions in immune and growth fac-
tors are already present in schizophrenia and MDD from disease onset.
Altered glucose metabolism factors seem to be already present in
schizophrenia only.
Below we will discuss findings concerning growth factors, immune
factors and glucose metabolism separately in more detail.
Fig. 7. Forest Plot Showing Effect Sizes for Glucose Metabolism Factors in Drug-Naïve First-Episode Schizophrenia and MDD.
Diamonds illustrate the summary effect sizes, the middle of each diamond represents the summary effect size, and the width of the diamond depicts the width of the
overall 95% CI. Abbreviations: MDD, major depressive disorder.
Fig. 8. Fasting Glucose Levels in Patients with Drug-Naïve First-Episode Schizophrenia or MDD and Controls.
Each square resembles the effect size for a single study. The horizontal line running through each square illustrates the width of the 95% CI. The size of the squares
reflects the weight attributed to each study. Diamonds illustrate the summary effect sizes and the width of the diamonds reflect the width of the overall 95% CI.
Abbreviations: MDD, Major Depressive Disorder.
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4.1. Growth factors
Deficient myelination leading to dysfunctional interneuron activity
and excessive excitatory pruning during (late) adolescence is thought to
underlie schizophrenia (Insel, 2010). It has been hypothesized that
impairment of neuroplasticity is implicated in the pathophysiology of
both MDD and schizophrenia (Rao et al., 2017). Growth factors, such as
BDNF and NGF, contribute to maintaining the plasticity of neurons. Our
findings of decreased BDNF and NGF levels in schizophrenia and a si-
milar trend of decreased BDNF and NGF levels in MDD are in line with
meta-analyses with less strict inclusion criteria (i.e., drug-free, medi-
cated or long-term patients). BDNF levels were found to be decreased in
drug-free schizophrenia patients (not exclusively drug-naïve) and in
first-episode schizophrenia patients, (Fernandes et al., 2015) as well as
in antidepressant-free multi-episode depressed patients, comparable
with current findings (Molendijk et al., 2014). In the meta-analysis of
Rao and colleagues, NGF levels were decreased in both schizophrenia
and MDD (Rao et al., 2017).
VEGF is a signal protein that promotes vasculogenesis and angio-
genesis, (Misiak et al., 2018) and is involved in neurogenesis in the
adult brain (Misiak et al., 2018). In the meta-analysis of Misiak and
colleagues, VEGF levels were unaltered in first-episode schizophrenia
patients, but decreased in multi-episode medicated schizophrenia pa-
tients (Misiak et al., 2018). These findings might reflect effects of se-
lection bias, illness progression, medication effects or comorbidities
such as hypertension or diabetes. In contrast, VEGF levels were elevated
in drug-naïve first-episode MDD patients compared with controls. In-
terestingly, links between VEGF-related single nucleotide poly-
morphism and risk for MDD have been presented by a genome wide
association study, demonstrating a relationship between VEGF genetic
determinants and MDD specifically (Xie et al., 2017). Furthermore, it
has been demonstrated that VEGF might be regulated by proin-
flammatory cytokines in patients with MDD (Schmidt et al., 2011).
4.2. Immune factors
Our current meta-analysis shows that signs of a low-grade periph-
eral inflammation are recognizable in both drug-naïve first-episode
schizophrenia and MDD. Notably, mainly pro-inflammatory cytokines
(i.e., TNFα and IL-6) seem to be dysregulated at disease onset in both
schizophrenia and MDD patients. Our findings are in line with two
other meta-analyses which reported increased levels of IL-6 and TNFα
in medication-naïve first-episode psychosis patients and multi-episode
MDD patients (Kohler et al., 2017; Upthegrove et al., 2014). We ob-
served elevated CRP levels in MDD patients and a trend of elevated CRP
levels in schizophrenia patients, with similar effect sizes. Subclinical
systemic inflammation has been associated with an increased risk of
new onset depression, psychosis and other psychiatric disorders (Pasco
et al., 2010; Osimo et al., 2018).
Despite these similarities found in schizophrenia and MDD, we also
observed a differentiated representation of other immune related
compounds in schizophrenia and MDD. In the current study, IL-2 was
elevated in MDD patients compared with controls. IL-2 plays an im-
portant role in activating regulatory T-cells which control inflamma-
tion. It is unclear whether these increased IL-2 levels are a reaction to
the ongoing inflammation in patients with MDD. Currently, low-dose
IL-2 trials are ongoing aiming at decreasing depressive symptoms (Ellul
et al., 2018). For IL-4 we observed a trend of increased levels in schi-
zophrenia. IL-4 activates B-cell and T-cell proliferation and is a target in
the treatment of allergies (anti-IL4/anti-IL13 combination therapy)
(Gooderham et al., 2018). IL-8 is a chemokine and, among other pro-
cesses, primarily attracts neutrophils to infection sites (Nordsieck et al.,
2018). We found in our meta-analysis that IL-8 was increased in schi-
zophrenia and decreased in MDD. TGF-β has regulatory properties in
regard to the immune system. For TGF-β we observed a trend of de-
creased levels in MDD (Massague, 2012).
Similar to our study, Goldsmith and colleagues reported elevated
levels of IL-6 and TNFα in acutely ill psychosis patients and acutely ill
MDD patients – even though the majority was not drug-naïve
(Goldsmith et al., 2016). Elevated levels of IFNγ, IL-1β, IL-8, IL-10, and
IL-12 in acutely ill psychosis patients compared with controls were
reported, of which we found the same direction of alteration for these
compounds, but not significantly for each compound (Goldsmith et al.,
2016). As compared to our study, Goldsmith et al. found the same di-
rection of alterations, but significant, for IL-12, IFNγ and IL-4 in acutely
ill MDD patients (Goldsmith et al., 2016). In contrast, we observed
increased levels of IL-4 in current meta-analysis, and Goldsmith and
colleagues reported decreased IL-4 levels in acutely ill psychosis
(Goldsmith et al., 2016). Most differences are likely derived from the
fact that we lacked power for most compounds, since we could gen-
erally include less studies due to our strict drug-naïve study criteria.
However, some differences could have been influenced by medication
effects, such as the IL-4 levels (Sobis et al., 2015).
4.3. Prodromal course and inflammation
Schizophrenia often shows a prodromal course in which immune-
mechanisms may already play a role. Genetic association studies
showed that the immune system of patients with schizophrenia is subtly
more prone to activation, as expressed for example in major histo-
compatibility complex molecules, (Debnath et al., 2013; Mokhtari and
Lachman, 2016) its enhancers, (Takao et al., 2013) and environmental
factors that activate the immune system (i.e. prenatal infection and the
experience of stress), may put components of the immune system in an
altered state of activity (Fineberg and Ellman, 2013; Brown and Derkits,
2010). A prospective general population birth cohort study found an
association between higher inflammatory marker IL-6 in childhood (at
age 9) and the development of psychosis in young adulthood
(Khandaker et al., 2014). A longitudinal study showed that 15 immune-
related compounds can predict conversion to psychosis in a clinical-
high risk for psychosis group (Perkins et al., 2015). Also, baseline TNFα
and IL-6 could predict negative symptom trajectories in persons at
clinical-high risk for psychosis, independent of baseline depression
(Goldsmith et al., 2019).
For MDD, there is less evidence for an inflammatory prodromal
course, but some data suggests that inflammation could be a precursor
for developing depression. The same prospective birth cohort study
mentioned above for psychosis, also found associations between ele-
vated IL-6 levels, measured at age 9, and specific symptoms of de-
pression (i.e. diurnal variation in mood, concentration difficulties, fa-
tigue and sleep disturbances) at age 18 years after adjusting for
potential confounders (including self-reported infections) (Khandaker
et al., 2014; Chu et al., 2019). Indeed, associations have been found
between polymorphisms in immune genes and MDD (Debnath et al.,
2013; Mokhtari and Lachman, 2016; Barnes et al., 2017). However,
there are inconsistencies between the immune effects of these genetic
variants and the resulting effects on depression (Barnes et al., 2017).
Environmental and gene × environmental interactions are likely to
have a greater influence on inflammation in depression than genetic
variants alone, whereby the expression of some polymorphisms may
only become evident when accompanied with life stressors (Barnes
et al., 2017). Furthermore, epidemiologic studies have shown that
early-life infections and auto-immune diseases (including diabetes) are
linked with developing schizophrenia or depression later in life (Benros
et al., 2013; Benros et al., 2014; Kohler-Forsberg et al., 2018).
4.4. Inflammatory subtypes
The inflammatory dysregulations found in schizophrenia and MDD
could indicate that low-grade inflammation is present in both disorders,
at least in some patients. Inflammatory subtypes could be present
among patients with schizophrenia or MDD. However, a meta-analysis
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looking at immune factors found evidence against the existence of an
immune subgroup of psychosis (Pillinger et al., 2018). Lower variability
of especially IL-6 found in psychosis patients could represent a core
component in the immunobiology of psychosis (Pillinger et al., 2018).
These findings suggest that an inflammatory subtype cannot be defined
using peripheral immune data. The evidence presented by Pillinger and
colleagues could indicate that immune alterations in schizophrenia
patients are truly a sign of intrinsic immune dysfunction, instead of a
feature of physiological differences between patients and controls, such
as age, sex, body-mass index (BMI), and ethnicity. However, only a
small proportion of the included studies matched for these confounders.
Conversely, another study found genetic evidence for an immune-re-
lated subgroup of schizophrenia (Trossbach et al., 2019).
MDD is a highly heterogeneous disorder and the presence of an
inflammatory subtype could be relevant in this disorder. Data from a
longitudinal cohort study showed that higher inflammatory markers
(CRP, IL-6, and TNFα), BMI, and metabolic syndrome components are
associated with the atypical subtype, not with melancholic depression
(Lamers et al., 2013). A subsequent study, using network analysis,
showed that the most likely symptoms to share associations with in-
flammatory markers are: sleep problems, energy level, appetite/weight
change, aches and pains, and irritability (adjusted for age, sex, BMI,
exercise, smoking, alcohol, and chronic diseases) (Fried et al., 2019).
Fried and colleagues observed that BMI was strongly associated with
CRP (Fried et al., 2019). Given that CRP is released in adipose tissue, an
increase in appetite and weight would be expected to be associated with
CRP. Lamers and colleagues showed indeed that increased appetite was
related to inflammation, specifically CRP and TNFα (Lamers et al.,
2018). A longitudinal population-based study found an unidirectional
association between current MDD subtype with atypical features and
high-sensitivity CRP levels at follow-up – suggesting that inflammation
may be a consequence of this condition (Glaus et al., 2018). Increasing
evidence shows that inflammation may play an important role in an
etiologically distinct depression subtype, characterized by resistance to
antidepressant medication (Barnes et al., 2017; Hughes and Kumari,
2017). Of note, Rantala and colleagues proposed a model of multiple
subtypes of depression, based on proximate mechanisms that caused the
depressive episode (e.g., infection, long-term stress, and somatic dis-
eases) (Rantala et al., 2018). In short, modern lifestyle could increase
susceptibility to inflammatory dysregulation and chronic stress, which
both increase peripheral proinflammatory cytokines, leading to low
mood and sickness behavior. Inflammation may aggravate the pre-
viously adapted short-term mood changes to a chronic dysfunctional
depressive state by preventing the normalization of mood, escalating
into an episode of MDD. For an elaborative discussion on this topic see
(Rantala et al., 2018).
Finally, the inflammation present in schizophrenia and MDD, at
least in high-inflammatory subgroups, is in line with large epidemio-
logical studies that reported an increased prevalence of immune dis-
eases in both schizophrenia and MDD including type 1 diabetes mel-
litus, but with notable exceptions such as rheumatoid arthritis (Eaton
et al., 2006; Benros et al., 2012; Sellgren et al., 2014).
4.5. Glucose metabolism
In this meta-analysis, evidence for a dysfunctional glucose meta-
bolism was found in drug-naïve first-episode patients with schizo-
phrenia, but not in those with MDD. Although alterations in glucose
metabolism are observed frequently during use of antipsychotics, it has
become clear that an altered state of glucose homeostasis in schizo-
phrenia is present from the onset of the disorder, even when comparing
antipsychotic-naïve first-episode cases with BMI-matched controls
(Pillinger et al., 2017). Indeed, the presence of diabetes in schizo-
phrenia was already reported well in the 19th century, long before the
advent of antipsychotics and eating habits did not easily induce meta-
bolic dysfunctions as they do today (Kohen, 2004). ‘Diabetes is a
disease which often shows itself in families in which insanity prevails’
as stated in the book ‘The Pathology of Mind’ written in 1879
(Maudsley, 1879). In the 17th century, Thomas Willis, a physician who
observed that the urine is sweet in patients with diabetes (glycosuria),
stated that diabetes was caused by ‘sadness or long sorrow and other
depressions’ (Willis, 1971). As of today, meta-analytic evidence showed
that MDD increases the risks of hyperglycemia, insulin resistance and
type 2 diabetes (Kan et al., 2013; Mezuk et al., 2008). Garcia-Rizo and
colleagues showed that patients with a serious mental illness have an
altered glycemic homeostasis already at onset of the disease, (Garcia-
Rizo et al., 2016) as measured with a two hour glucose load. Im-
plicating that a similar glycemic pathway might be shared between
serious mental illnesses. Indeed, similar prevalence for metabolic syn-
drome in schizophrenia (33.4%) and MDD (31.3%) has been presented
(Vancampfort et al., 2015). Glycemic abnormalities might have a fa-
milial background, as psychiatric disorders and endocrine auto-immune
diseases (including diabetes) have a relatively high familial co-occur-
rence. Psychiatric disorders and endocrine auto-immune diseases could
be the cause or consequence of each other – i.e. immune pathogenic
factors and environmental (stress) factors for psychiatric disorders and
endocrine autoimmune diseases may be shared (Eaton et al., 2010;
Steiner et al., 2014; Garcia-Rizo et al., 2015). However, in our meta-
analysis we only observed a trend of elevated fasting glucose levels in
drug-naïve first-episode MDD patients. The results of glucose metabo-
lism markers in MDD should be interpreted with caution owing to the
small sample size of the studies included in these analyses.
4.6. Clinical relevance
Given the alterations in immune, growth, and glucose metabolism
factors in schizophrenia and MDD, it is worthwhile to consider the
clinical relevance of these alterations. Firstly, associations between in-
flammation and metabolic dysfunction, and treatment response have
been found in schizophrenia and MDD. Psychosis patients with high
inflammation have a worse treatment response to antipsychotics com-
pared with psychosis patients with low inflammation. Nettis and col-
leagues found an association between increased high-sensitivity CRP,
triglycerides, and BMI at baseline, and higher Positive and Negative
Syndrome Scale scores and reduced rate of treatment response at 1-year
follow-up using a factor analysis in a longitudinal study of first-episode
psychosis patients (Nettis et al., 2019). A multinational, multi-centered,
randomized, double-blind study used a clustering approach to stratify
325 first-episode psychosis patients into four clinical subtypes. Those
with the most severe symptoms were the most at risk of non-remission.
This group of patients exhibited before treatment higher serum levels of
several pro-inflammatory compounds compared with the other patient
groups (Martinuzzi et al., 2019).
MDD patients with high inflammation also seem to be more prone
for chronicity. Regular antidepressant treatment fail in over 30% of
patients with a depression, and those with high inflammation and/or
BMI are in particular resistant to treatment (Bekhbat et al., 2018;
Haroon et al., 2018). A longitudinal cohort study showed that high IL-6
levels at baseline could predict chronicity of depression (Lamers et al.,
2019). Moreover, a meta-analysis showed that signs of inflammation
contribute to treatment resistance in patients with depression
(Strawbridge et al., 2015).
Secondly, signs of inflammation or metabolic dysfunction in schi-
zophrenia and MDD readily suggest augmentation therapy for those
patients in which the underlying pathophysiology is related to in-
flammatory or metabolic dysfunctions. Although antipsychotics already
have some anti-inflammatory actions (Hu et al., 2012), a meta-analysis
on the efficacy of augmentation with anti-inflammatory agents for pa-
tients with schizophrenia showed that the anti-inflammatory agents
aspirin, estrogens, minocycline, and N-acetylcysteine improved
symptom severity (Cakici et al., 2019). In depression TNF has been
consistently shown to be elevated. Bekhbat and colleagues observed
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that TNF antagonism seems to be in particular effective in patients with
treatment-resistant depression with high inflammation (CRP > 5 mg/
L), and elevated plasma lipids and cholesterols (Bekhbat et al., 2018).
Also, there is meta-analytic evidence for beneficial effects of other anti-
inflammatory agents, in particular celecoxib, for improving symptom
severity in depression (Kohler et al., 2014).
Taken together, both schizophrenia and MDD have a heterogenous
presentation of symptoms which could also apply for their underlying
disease biological mechanisms. However, further research is warranted
to identify whether growth factor, inflammatory and/or metabolic
subgroups are present, and if so, which underlying disease biological
mechanisms are responsible. The latter readily suggests research into
advanced diagnostics and augmentation therapy for those subgroups.
Possibly in the future, a blood-based clinical decision support system in
schizophrenia and MDD could identify inflammatory and/or metabolic
aberrant subgroups, in order to augment their regular therapy with
anti-inflammatory or metabolic medications.
4.7. Limitations
To our best knowledge, this is the first meta-analysis that analyzes
peripheral growth, immune and glucose metabolism compounds in
drug-naïve first-episode patients with schizophrenia and drug-naïve
first-episode patients with MDD compared with healthy controls.
Ideally, for a meta-analysis, a sufficient number of studies and sample
sizes is needed (e.g., at least 5 studies). However, based on our ap-
proach to include only drug-naïve first-episode patients, we could make
a better estimation of the alterations in compounds measured in per-
ipheral blood, without the influence of treatment or chronic illness.
Therefore, our significant findings of altered compounds in schizo-
phrenia and MDD are truly not influenced by chronicity or medication
effects. The compounds that were analyzed in a meta-analysis of less
than five studies merit further investigation. When interpreting the
results, one should take into account that the number of studies and
sample sizes differed among the two disorders for each compound.
Unfortunately, evidence regarding peripheral blood compounds in
drug-naïve first-episode MDD patients is relatively scarce. Therefore,
due to our strict study criteria of including only drug-naïve first-episode
patients, we could include less and smaller sample size studies for MDD
than for schizophrenia. Possibly, more drug-naïve first-episode schizo-
phrenia studies have been published, because in clinical care the im-
plementation of early recognition teams for first-episode psychosis has
become a standard intervention over the years whereas, this is less so
for MDD (McGorry, 2015). Not all cytokines, either pro- or anti-in-
flammatory, have been sufficiently investigated to include them into
our meta-analysis. Another important limitation is that we did not in-
clude other major psychiatric disorders such as bipolar disorder. Gen-
erally, schizophrenia and bipolar disorder are seen as more related to
one another than schizophrenia and depression. As a consequence,
there is a substantial body of research investigating similarities between
schizophrenia and bipolar disorder, both from a clinical perspective, as
well as the biological underpinnings of both disorders. However, only
recently, trends diagnostics approaches have been applied to schizo-
phrenia and major depression. Current findings therefore could point at
transdiagnostic biological disturbances, underscoring the importance of
studying neurobiologic disturbance more broadly in psychiatric dis-
orders.
5. Conclusions
We found meta-analytic evidence that dysfunctions in peripheral
growth and immune factors are already present in schizophrenia and
MDD from disease onset. An altered glucose homeostasis might be
uniquely present at the onset of schizophrenia. More drug-naïve and
first-episode studies, especially for MDD, are needed for further vali-
dation of our results. Our findings suggest further research into the
importance of developing advanced diagnostics – possibly a blood-
based clinical decision support system – and augmentation therapy with
anti-inflammatory or metabolic agents for those with high inflamma-
tion or metabolic disturbances.
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